Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
Returns on capital
Fate Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-65.8%
avg -51.3%
ROIC
-51.4%
avg -40.2%
ROA
-42.7%
avg -35.6%
Analysis
ROA is currently the strongest return metric at -42.7% versus its period average of -35.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Bahram Valamehr | President, Chief Executive Officer & Director | USD 964.7K | 49 | 591.82K | 0.51% |
Cindy R. Tahl | Chief Legal & Compliance Officer and Corporate Secretary | USD 732.7K | 53 | — | — |
Kamal Adawi | CFO & Treasurer | USD 541.97K | 47 | 93.42K | 0.08% |
Ryan Douglas | Senior Director of Investor Relations & Business Development | — | — | — | — |
Jessica Francis | Senior Vice President of Human Resources & Operations | — | — | — | — |
Kate Duvall | Corporate Controller | — | — | — | — |
Martin Hosking | Head of Research | — | — | — | — |
James Archie Harrell Jr. | Senior Vice President of Market Development & Commercial Operations | — | 56 | — | — |
Tunde Babalola | Senior Vice President of Technical Operations & Quality | — | — | — | — |
Yu Cai | Head of Intellectual Property & Assistant General Counsel | — | — | — | — |
Andrew Henry | Senior Vice President of Clinical Operations | — | 62 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
7
$336,429.23
Net Transaction Value
−$336,429.23
Net selling
Most Active
Valamehr Bahram
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 3, 26Nov 3, 2026 | Adawi Kamal Direct | Sell | $13.5K$13,524.69 |
| Aug 4, 26Aug 4, 2026 | Valamehr Bahram Direct | Sell | $108.1K$108,100.83 |
| Aug 4, 26Aug 4, 2026 | TAHL CINDY Direct | Sell | $95.4K$95,405.32 |
| May 20, 26May 20, 2026 | TAHL CINDY Direct | Sell | $48.1K$48,083.61 |
| May 20, 26May 20, 2026 | Valamehr Bahram Direct | Sell | $54.5K$54,482.16 |
| Jan 9, 26Jan 9, 2026 | TAHL CINDY Direct | Sell | $11.3K$11,275.17 |
| Jan 9, 26Jan 9, 2026 | Valamehr Bahram Direct | Sell | $5.6K$5,557.45 |
Summary
Insiders reported 0 buys worth $0.00 and 7 sells worth $336,429.23 over the last 12 months. That adds up to net selling of $336,429.23. Valamehr Bahram was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -59.0% | +73.8% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -59.0% over three years. Forward estimates point to Revenue at +73.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Fate Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about FATE's management, answered from reported figures.
Who manages FATE?
Fate Therapeutics, Inc. (FATE) lists 11 active executives. The top listed executive is Ryan Douglas, Senior Director of Investor Relations & Business Development.
Are FATE insiders buying or selling?
Recent insider activity shows net buying of $42.14M.
Continue the stock analysis
Jump to another research area for this company.